NS5A resistance-associated substitutions in patients with genotype 1 hepatitis C virus: Prevalence and effect on treatment outcome.
about
Understanding Hepatitis C Virus Drug Resistance: Clinical Implications for Current and Future Regimens.Resistance Mechanisms in Hepatitis C Virus: implications for Direct-Acting Antiviral Use.Searching for synergy: Identifying optimal antiviral combination therapy using Hepatitis C virus (HCV) agents in a replicon system.Real-World Experiences with the Combination Treatment of Ledipasvir plus Sofosbuvir for 12 Weeks in HCV Genotype 1-Infected Japanese Patients: Achievement of a Sustained Virological Response in Previous Users of Peginterferon plus Ribavirin with HCVAntiviral Activity and Resistance Analysis of NS3/4A Protease Inhibitor Grazoprevir and NS5A Inhibitor Elbasvir in Hepatitis C Virus GT4 Replicons.Resistance testing for the treatment of chronic hepatitis C with direct acting antivirals: when and for how long?Optimal cure rate by personalized HCV regimens in real-life: a proof-of-concept study.Sofosbuvir (SOF) Suppresses Ledipasvir (LDV)-resistant Mutants during SOF/LDV Combination Therapy against Genotype 1b Hepatitis C Virus (HCV).Retreatment with sofosbuvir plus grazoprevir/elbasvir plus ribavirin of patients with hepatitis C virus genotype 1 or 4 who previously failed a NS5A or NS3-containing regimen. ANRS HC34 REVENGE.Advances in the treatment of HIV/HCV coinfection in adults.All-oral DAA therapy against HCV in HIV/HCV-coinfected subjects in real-world practice: Madrid-CoRe Findings.Ultra-Deep Genomic Sequencing of HCV NS5A Resistance-Associated Substitutions in HCV/HIV Coinfected Patients.Viral kinetics analysis and virological characterization of treatment failures in patients with chronic hepatitis C treated with sofosbuvir and an NS5A inhibitor.Hepatitis C virus deep sequencing for sub-genotype identification in mixed infections: A real-life experience.Sofosbuvir/Velpatasvir/Voxilaprevir: A Pan-Genotypic Direct-Acting Antiviral Combination for Hepatitis C.Current and future challenges in HCV: insights from an Italian experts panel.Prevalence and impact of baseline resistance-associated substitutions on the efficacy of ledipasvir/sofosbuvir or simeprevir/sofosbuvir against GT1 HCV infection.Resistance to DAAs: When to Look and When It Matters.Ledipasvir/sofosbuvir for treatment-naive and treatment-experienced Chinese patients with genotype 1 HCV: an open-label, phase 3b study.Sequencing of hepatitis C virus for detection of resistance to direct-acting antiviral therapy: A systematic review.geno2pheno[ngs-freq]: a genotypic interpretation system for identifying viral drug resistance using next-generation sequencing data.Recent update of the 2017 Korean Association for the Study of the Liver (KASL) treatment guidelines of chronic hepatitis C: comparison of guidelines from other continents, 2017 AASLD/IDSA and 2016 EASL.Prevalence of Single and Multiple Natural NS3, NS5A and NS5B Resistance-Associated Substitutions in Hepatitis C Virus Genotypes 1-4 in Italy.Baseline resistance-guided therapy does not enhance the response to interferon-free treatment of HCV infection in real lifeHepatitis C resistance to NS5A inhibitors: Is it going to be a problem?Resistance Analysis of a 3-Day Monotherapy Study with Glecaprevir or Pibrentasvir in Patients with Chronic Hepatitis C Virus Genotype 1 InfectionNatural polymorphisms in the resistance associated sites of HCV-G1 NS5B domain and correlation with geographic origin of HCV isolatesPretreatment Hepatitis C Virus NS5A/NS5B Resistance-Associated Substitutions in Genotype 1 Uruguayan Infected Patients2017 KASL clinical practice guidelines management of hepatitis C: Treatment of chronic hepatitis C
P2860
Q38618427-EF7D8616-3D1A-4A9B-86AB-D9004F24F32CQ39301797-C46947C7-74AC-40F6-B1A3-E3AF34024FBEQ40052719-13F0ADC9-41AB-4C86-8510-352652F89881Q40228687-4ADE0D47-672D-4FB3-B11E-A3E1942B25F5Q40239514-B99D24E1-D739-489A-B2FC-D035C53BB6B5Q40282635-E605A74E-0F50-4769-B227-68BA5E27EB8FQ41927870-92F93F85-63B4-4E7E-9A65-D2B473207F04Q44519022-A871EE6B-310B-432F-A767-59D6D1A75F96Q45325577-EC0190D6-BBF8-4C13-9DC1-3B8D8DF2653EQ47291511-6BB5864A-27FA-44F6-BC62-9ABB141B8841Q47548361-39EB027C-03AA-4DF4-B95E-A4436A7F53F4Q47554082-F78FFD0D-0552-4B43-BEA6-8CA486FF6737Q47561388-FE7329C3-848C-4CCE-8724-4B7E191E28C9Q47564117-9F9C3AA9-9CB2-40BB-9A66-3140465AF926Q47587210-9CA88FD1-E5A7-4CBE-A71C-36702BAC02E2Q47591971-70AB0F30-951A-4896-B41A-A58DC4EB790CQ49911983-131A5935-F648-4119-9F88-75DD19E7E37EQ50108357-C39527CB-E4DF-4E68-A187-3E424F506E06Q52594744-F2C9A10C-F29B-446E-AB68-5F3D0086FEBCQ52699078-12775EC3-82F8-4F58-8FEC-4212442D707FQ52803596-1A337DDE-34B1-4B50-BD82-2BFA27F719FEQ54223871-01D8DE87-4B56-451A-B711-302A86263738Q55379857-3F0E1227-739F-48B2-A0A4-4ADD202B9AD8Q57296265-CF145335-FAAF-4008-BF1A-A6E60C9CA034Q57491238-6C5C23C9-9C3C-4943-8247-42D2CB079D12Q58697287-28D51EFA-8B5E-4B08-8C3E-AB6AFB732924Q58725182-3511DB26-7317-413D-8656-D82D6F236990Q58780610-C0EC7156-F783-4DEE-B196-0694CD49907DQ58788714-A85D29B6-F69D-42FB-93F2-795D9FBBE03F
P2860
NS5A resistance-associated substitutions in patients with genotype 1 hepatitis C virus: Prevalence and effect on treatment outcome.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
NS5A resistance-associated sub ...... d effect on treatment outcome.
@en
NS5A resistance-associated sub ...... d effect on treatment outcome.
@nl
type
label
NS5A resistance-associated sub ...... d effect on treatment outcome.
@en
NS5A resistance-associated sub ...... d effect on treatment outcome.
@nl
prefLabel
NS5A resistance-associated sub ...... d effect on treatment outcome.
@en
NS5A resistance-associated sub ...... d effect on treatment outcome.
@nl
P2093
P50
P1476
NS5A resistance-associated sub ...... d effect on treatment outcome.
@en
P2093
Alessandra Mangia
Brian Doehle
Charlotte Hedskog
Chohee Yun
Diana M Brainard
Evguenia Svarovskaia
Gregory J Dore
Hadas Dvory-Sobol
Hongmei Mo
Ira Jacobson
P304
P356
10.1016/J.JHEP.2017.01.007
P577
2017-01-17T00:00:00Z